Yohana Kefella

Yohana Kefella

Auto-generated profile, based on publicly available information

Yohana Kefella

Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
BNBoting Ning
Boting Ning
DCDarren J. Chiu
Darren J. Chiu
RPRoxana M. Pfefferkorn
Roxana M. Pfefferkorn
ECErin Cullinane
Erin Cullinane
YKYohana Kefella
Yohana Kefella
JBJennifer Beane
Jennifer Beane
Bronchial premalignant lesions (PML), precursors of lung squamous cell carcinoma, have distinct molecular subtypes. The proliferative subtype, enriched with bronchial dysplasia, had decreased expression of an antigen-processing/presentation gene coexpression module in progressive/persistent versus regressive PMLs, suggesting a functional impact of these genes on immune evasion. In this study, we performed miRNA sequencing, miRNA in situ hybridization, and spatial proteomics of bronchial biopsies from patients at high risk for lung cancer. An miRNA–gene network analysis identified hsa-miR-149-5p as a potential regulator of the antigen presentation gene module. Staining on adjacent biopsy tissue showed that hsa-miR-149-5p was predominantly expressed in the epithelium and upregulated in progressive/persistent proliferative lesions. Targets of this miRNA, the transcriptional coactivator of MHC-I gene expression, NLRC5, and the genes it regulates, were downregulated in these lesions. Decreased NLRC5 expression reduced both IFNγ-induced MHC-I surface expression and CD8 T-cell cytotoxicity in lung squamous cancer cells. In PMLs, basal cells with high levels of NLRC5 were in close spatial proximity to CD8 T cells, suggesting that these cells exhibit increased functional MHC-I gene expression in vivo. These findings indicate a functional role for hsa-miR-149-5p in PML progression/persistence and suggest this axis as a potential therapeutic target for PML immunomodulation.

2 April 2026
Verified
Other
Open access
BNBoting Ning
Boting Ning
DCDarren J. Chiu
Darren J. Chiu
RPRoxana M. Pfefferkorn
Roxana M. Pfefferkorn
ECErin Cullinane
Erin Cullinane
YKYohana Kefella
Yohana Kefella
JBJennifer Beane
Jennifer Beane
Supplementary Figure S4. Expression of hsa-miR-149-5p was up-regulated and expression of NLRC5 was downregulated in LUSC tumor compared to adjacent benign tissue.

2 April 2026
Verified
Other
Open access
BNBoting Ning
Boting Ning
DCDarren J. Chiu
Darren J. Chiu
RPRoxana M. Pfefferkorn
Roxana M. Pfefferkorn
ECErin Cullinane
Erin Cullinane
YKYohana Kefella
Yohana Kefella
JBJennifer Beane
Jennifer Beane
Supplementary Figure S3. Expression level of hsa-miR-149-5p was significantly negatively correlated with that of NLRC5 in lung-related datasets.


2 April 2026
Verified
Other
Open access
BNBoting Ning
Boting Ning
DCDarren J. Chiu
Darren J. Chiu
RPRoxana M. Pfefferkorn
Roxana M. Pfefferkorn
ECErin Cullinane
Erin Cullinane
YKYohana Kefella
Yohana Kefella
JBJennifer Beane
Jennifer Beane
Supplementary Figure S6. Correlation between hsa-miR-149-5p and NLRC5 expression levels within the samples from the FANTOM5 project.

2 April 2026
Verified
Other
Open access
BNBoting Ning
Boting Ning
DCDarren J. Chiu
Darren J. Chiu
RPRoxana M. Pfefferkorn
Roxana M. Pfefferkorn
ECErin Cullinane
Erin Cullinane
YKYohana Kefella
Yohana Kefella
JBJennifer Beane
Jennifer Beane
Bronchial premalignant lesions (PML), precursors of lung squamous cell carcinoma, have distinct molecular subtypes. The proliferative subtype, enriched with bronchial dysplasia, had decreased expression of an antigen-processing/presentation gene coexpression module in progressive/persistent versus regressive PMLs, suggesting a functional impact of these genes on immune evasion. In this study, we performed miRNA sequencing, miRNA in situ hybridization, and spatial proteomics of bronchial biopsies from patients at high risk for lung cancer. An miRNA–gene network analysis identified hsa-miR-149-5p as a potential regulator of the antigen presentation gene module. Staining on adjacent biopsy tissue showed that hsa-miR-149-5p was predominantly expressed in the epithelium and upregulated in progressive/persistent proliferative lesions. Targets of this miRNA, the transcriptional coactivator of MHC-I gene expression, NLRC5, and the genes it regulates, were downregulated in these lesions. Decreased NLRC5 expression reduced both IFNγ-induced MHC-I surface expression and CD8 T-cell cytotoxicity in lung squamous cancer cells. In PMLs, basal cells with high levels of NLRC5 were in close spatial proximity to CD8 T cells, suggesting that these cells exhibit increased functional MHC-I gene expression in vivo. These findings indicate a functional role for hsa-miR-149-5p in PML progression/persistence and suggest this axis as a potential therapeutic target for PML immunomodulation.